Stabilizing Psilocybin Pharmacology and Tuning Safety with Atypical Antipsychotic Cotherapy
Anna C. Renner, Robert B. Kargbo
ACS Medicinal Chemistry Letters October 10, 2025 DOI: 10.1021/acsmedchemlett.5c00595 via OpenAlex
Summary
AI-generated from the abstractA new crystalline cocrystal combining psilocin and psilocybin increases drug exposure, boosts markers of neuroplasticity, and alters functional brain activity. Adding atypical antipsychotics to the treatment changes serotonin signaling, reducing safety risks linked to the 5-HT2B receptor, which is associated with heart valve problems. These chemical advances improve how the therapy works, its selectivity for desired effects, and the ability to measure its impact in lab models. Together, they offer a chemistry-based way to develop scalable psychedelic treatments that are safer for the heart and produce lasting neuroplastic changes, as shown in organoid and animal studies.
Study at a glance
| Characteristics | Preclinical study Peer reviewed |
|---|---|
| Population | Organoid and animal models |
| Interventions | crystalline cocrystal of psilocin and psilocybin adjunctive atypical antipsychotics |
| Key finding | A crystalline cocrystal of psilocin and psilocybin enhances exposure, neuroplasticity biomarkers, and functional activity, while adjunctive atypical antipsychotics modulate serotonergic signaling to mitigate 5-HT2B-linked safety concerns. |
Abstract
A crystalline cocrystal of psilocin and psilocybin enhances exposure, neuroplasticity biomarkers, and functional activity, while adjunctive atypical antipsychotics modulate serotonergic signaling to mitigate 5-HT2B-linked safety concerns. Together, these inventions advance formulation, mechanistic selectivity, and translational biomarkersoffering a chemistry-enabled path to scalable psychedelic therapy with improved cardiac safety and durable neuroplastic responses across organoid and animal models.